Evidence and Experience in Managing Patients with or at High Risk of ASCVD

Learning Objectives

• Explain why escalation of therapy beyond statins with nonstatin therapies is beneficial to reduce ASCVD risk
• Discuss recent data of omega-3 fatty acids and how these data may translate into clinical practice to reduce ASCVD events
• Apply professional society recommendations and expert opinion on a case-by-case basis for patients with or at high risk of ASCVD or at risk of further CV events